# Ciclophosphamide, Vincristine, Myocet and Prednisone, With Rituximab in 1st-Line Treatment for Patients With No-Hodgkin B Lymphoma and Cardiovascular (CV) Risk

> **NCT00849355** · PHASE2 · UNKNOWN · sponsor: **Asociacion Doctor Peset Para el Estudio de la Hematología** · enrollment: 44 (estimated)

## Conditions studied

- No Hodgkin B Lymphoma

## Interventions

- **DRUG:** RCOMP-14 + rituximab

## Key facts

- **NCT ID:** NCT00849355
- **Lead sponsor:** Asociacion Doctor Peset Para el Estudio de la Hematología
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-08
- **Primary completion:** 2009-11
- **Final completion:** 2010-11
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2009-02-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00849355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00849355, "Ciclophosphamide, Vincristine, Myocet and Prednisone, With Rituximab in 1st-Line Treatment for Patients With No-Hodgkin B Lymphoma and Cardiovascular (CV) Risk". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00849355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*